Day 1 :
Keynote Forum
John. T. McDevitt
New York University College of Dentistry, USA
Keynote: Programmable Bio-Nano-Chips for Quantitation of Drugs of Abuse in Oral Fluids
Time : 09:00-09:40
Biography:
Dr. John T. McDevitt will serve as the new Chairman for the Department of Biomaterials and Biomimetics within New York University College of Dentistry (NYUCD). McDevitt is a pioneer in the development of tools for affordable and accessible healthcare. He also serves as the Scientific Founder for and Chief Scientific Officer for SensoDx, LLC. His innovations have been awarded Best of What's New in the Medical Device Category in 2008 by Popular Science, Best Scientific Advance of the Year for 1998 by the Science Coalition and Nokia Sensing X Prize Finalist in 2013 and 2014.
Abstract:
Use of illicit drugs and abuse of licit counterparts are associated with multiple physical health, emotional, and interpersonal problems. Cardiovascular disease, stroke, cancer, HIV/AIDS, anxiety, depression, and sleep problems, financial difficulties and legal complications, work, and family problems can all result from or be exacerbated by drug abuse. In 2013, 21.6 million Americans were dependent on drugs or were drug abusers, representing 8.2% of our population aged 12 and over. In the U.S. each year drug abuse and drug addiction cost employers over $122 billion in lost productivity time and another $15 billion in health insurance costs. Routine screening for substance use disorders could alter this statistic and get more people the help they need. Indeed, since the inception of medication-assisted treatment (MAT) for opioid addiction, drug testing has provided both an objective measure of treatment efficacy and a tool to monitor patient progress.
Keynote Forum
Norman S Miller
Michigan State University, USA
Keynote: Marijuana and violence
Time : 09:40-10.20
Biography:
Abstract:
Keynote Forum
Ronald Bradley
Central Michigan University, USA
Keynote: Psychiatric medical home model; Medical, substance use disorders and mental health cost savings
Time : 10.20-11.00
Biography:
Ronald Howard Bradley, DO, PhD, FACN, works at Central Michigan University College of Medicine in Saginaw, Michigan. Board certified in pain medicine, addiction management, and forensic psychiatry, Dr. Bradley handles many types of psychiatric cases. He is Chief of Psychiatry for the University, and author of over 60 articles and book chapter contributor. In 1986, the American Osteopathic College of Neurology and Psychiatry awarded Dr. Bradley with a Sidney Kanef Memorial Award.
Abstract:
People with severe mental illness (SMI) die from the same chronic medical conditions as those in the general population (e.g., heart disease, diabetes, stroke, and pulmonary disease). However, these diseases are more common in people with SMI leading to death 25 years earlier than the general population. The modifiable health risk factors that contribute to these diseases smoking, obesity, hypertension, metabolic disorder, substance use, low physical activity, poor fitness and diet are also more common and have an earlier onset in people with SMI. Side effects of psychiatric medications, which may include weight gain and metabolic disorders, add to these health risks. The risk to African Americans with SMI is even greater due to existing racial health disparities.
Keynote Forum
Gregory Rudolf
American Board of Addiction Medicine, USA
Keynote: Non-opioid protocol for opioid detoxifi cation and/or transition to antagonist treatment
Biography:
Abstract:
- Addiction psychiatry
Location: Double Tree by Hilton Chicago - North Shore
Chair
John. T. McDevitt
New York University College of Dentistry, USA
Co-Chair
Mickael Naassila
University of Picardie, USA
Session Introduction
Michael Groat
The Menninger Clinic-Baylor College of Medicine, USA
Title: Transforming vicious cycles into virtuous ones: Psychodynamic perspectives on treatment of the addicted patient
Biography:
Abstract:
Thersilla Oberbarnscheidt
Central Michigan University, USA
Title: Cannabis- is it really a Medicine?
Biography:
Abstract:
Cannabis has been used in medicine for thousands of years for various medical conditions. Over the last decade it is increasingly getting used in the treatment of chronic pain. Cannabis has been shown to have some positive efficacy in the reduction of pain as an adjunct in therapy combined with opioids. Clinical studies published are mostly small in number and solely for neuropathic pain. Most studies that showed a clinical benefit were short in duration. Longer-term studies for more than 4 weeks have reported psychosis in the patients with percentages ranging from 36.3% to even 80%. Most patients report a long list of side effects associated with the use of cannabis. Symptoms reported are memory problems, problems with motor coordination and impaired judgment and more serious medical problems like cancer or cardiac ischemia.
Biography:
Norman S. Miller, MD, JD, PLLC, is the Medical Director, Detoxification and Residential Pro¬grams, Bear River Health at Walloon Lake; and the President, Health Advocates PLLC. Umer Farooq, MD, is a Clinical Assistant Professor, Michigan State University College of Human Medi¬cine; and the Director, Dual Diagnosis Program, Pine Rest Christian Mental Health Services.
Abstract:
Thersilla Oberbarnscheidt
Central Michigan University, USA
Title: Mechanisms of pain and opioid pharmacology
Biography:
Abstract:
Mickael Naassila
University of Picardie, USA
Title: Light Alcohol Intake During Adolescence Induces Alcohol Addiction In Model Of Schizophrenia
Biography:
Professor Mickael Naassila received his PhD in Neurosciences at the University of Rouen studying the mechanisms of action of acamprosate and the role of nitric oxide synthase in alcohol dependence in rats. During his postdoctoral training at the Pharmacology & toxicology dept of the Pharmacy school at the University of Kansas, he studied the transcriptional and post-transductional effects of alcohol on NMDA receptor subunits. Since coming at the University of Picardie Jules Verne in 2000, he has been working on the effect of early life ethanol exposure (in utero and/or adolescence) on the vulnerability to develop alcohol dependence. He was also involved in different clinical projects on the genetic vulnerability to develop a severe phenotype of alcohol dependence and alcohol liver disease He is the leader of a European project on the cognitive and emotional impact of binge drinking in young people and on the use of preclinical model to mimic this phenomenon in rodents to uncover neurobiological mechanisms underlying long term vulnerability to alcohol abuse. Currently he is the head of the Research Group on Alcohol & Pharmacodependences, one of the very rare laboratories in France seeking to elucidate neurobiological bases of alcohol dependence in pertinent animal models of the disease.
Abstract:
Schizophrenia is a mental disorder characterized by a series of positive, negative or cognitive symptoms but with also the particularity of exhibiting high rate of comorbid use of drugs of abuse. While more than 80%of schizophrenics are smokers, the second drug the most consumed is alcohol with dramatic consequences on frequency and intensity of psychotic episodes and on life expectancy. Here we investigated the impact of light alcohol intake during adolescence on the subsequent occurrence of alcohol addiction like behavior in neonatal ventral hippocampal lesion (NVHL) rats, a neurodevelopmental model of schizophrenia. Our findings demonstrated an increased liability to addictive behaviors in adult neonatal ventral hippocampal lesioned (NVHL) rats after voluntary alcohol intake during adolescence.
Deanna L Mulvihill
RN PhD, Multi-State privilage, USA
Title: Women, Trauma and Alcohol Dependency: Connections and Disconnections In Alcohol Treatment
Biography:
Women with alcohol dependence and PTSD with a history of IPV want help however the health and social services do not always recognize their calls for help or their symptoms of distress. Recommendations are made for treatment centers to become trauma-informed that would help this recognition.
Abstract:
Women who have experienced intimate partner violence (IPV) are at greater risk for physical and mental health problems including posttraumatic stress disorder (PTSD) and alcohol dependency. On their own IPV, PTSD and alcohol dependency result in significant personal, social and economic cost and the impact of all three may compound these costs. Researchers have reported that women with these experiences are more difficult to treat; many do not access treatment and those who do, frequently do not stay because of difficulty maintaining helping relationships. However, these women’s perspective have not been previously studied. The purpose of this study is to describe the experience of seeking help for alcohol dependency by women with PTSD and a history of IPV in the context in which it occurs.
Amnon Jacob Suissa
University of Quebec in Montreal, Canada
Title: Addiction and dual diagnosis : toward a psychosocial perspective and the DPA
Biography:
Amnon Jacob Suissa is a professor with the school of social work at Universite du Quebec à Montreal. He teaches courses on addictions as a social problem and the methodology of social intervention. With a constructivist approach to social problems, he is interested in the social determinants of addictions and their impact on intervention processes. He has a background in family therapy and sociology and is the author of several books and a hundred scientific articles on the phenomenon of medicalization of behaviors understood as pathologies or even diseases.
Abstract:
Contrary to the understanding of two separate conditions, addiction and mental health, the history of human behavior teaches us that we obtain more results by focusing on the persons and their social ties than on the problems. Applied to addictions and mental health, the psychosocial approach can help us better understand the phenomenon by including not only the individual with the addiction and mental conditions but also his social ties.
Hiranita Takato
National Center for Toxicological Research, Japan
Title: Induction of Dopamine Independent Reinforcement and a Target for Discovery of Stimulant Abuse
Biography:
He earned my Ph.D. in Graduate School of Pharmaceutical Sciences, Kyushu University, Japan,, and have been a postdoctoral research fellow in at the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). Also, I have been a Research Associate at University of Colorado at Boulder. I am currently a Visiting Scientist in the Division of Neurotoxicology, NCTR, FDA. I have published more than 30 papers in reputed journals and has been serving as an editorial board member of repute.
Abstract:
Sigma1 receptors are intracellular chaperones that translocate from their primary endoplasmic reticulum localization to different subcellular compartments upon agonist actions, and regulate ion channels and G-protein-coupled-receptor signaling. Reports have implicated 1Rs in various biological functions. On the other hand, the dopamine (DA) transporter (DAT) is known as a primary target underlying reinforcing effects of stimulants. However, past studies suggest that several atypical DAT inhibitors have low abuse potential, and are prospective leads for cocaine abuse treatments. However, it is unknown about a mechanism underlying the “atypical” property. I characterized the reinforcing effects of 1R agonists and investigated a potential interaction between DAT and 1R using a drug self-administration procedure in rats. Primary findings are as follows: (1) 1R agonists were not reinforcing in naïve rats; however, 1R agonists maintained self-administration responding above saline levels in rats with a reinforcement history of stimulants, but not of heroin or ketamine; (2) the induced reinforcing effects of 1R agonists were DA-independent; (3) several atypical DAT inhibitors functioned as a R antagonist; (4) a dual DAT/1R inhibition resulted in insurmountable antagonism of cocaine self-administration; however, self-administration of heroin or ketamine was insensitive to the dual inhibition. Thus, these results suggest that stimulants function as a specific inducer of DA-independent reinforcement mechanisms mediating 1Rs, which might shed light on understanding the mechanisms underlying the intractability of stimulant abuse to pharmacotherapy. Further, the results indicate a proof of concept that dual DAT/1R inhibition is a target for the discovery of medications specific for stimulant abuse.
- Dual Diagnosis treatment & Addictive disorders
Location: Double Tree by Hilton Chicago - North Shore
Chair
Norman S Miller
Michigan State University, USA
Co-Chair
Lesch Otto-Michael
Austrian Society of Addiction Medicine
Session Introduction
Priyamvada Sharma
Centre for Addiction Medicine, NIMHANS, USA
Title: Qualitative and Quantitative determination of solvent abuse
Biography:
Priyamvada Sharma is currently working in National Institute of Mental Health and Neuro Science. Bengaluru, Karnataka, India Join institution. Her research includes Simultaneous Determination of Morphine, Codeine, Pentazocine and Propoxyphene in Urine Using HPTLC
Abstract:
During the late nineteenth century several countries around the world started reporting problem of solvent abuse among adults and teenagers. Inhalant abuse is the intentional gasp of volatile substances because of their fast and pleasurable sensory experience. (Flanagan and Fisher 2008) A nationwide survey conducted in Korea reported that more than 90% of male teenagers and over 60 % of female teenagers have at least sniffed glue once in their lifetime. These substances give an intoxicating high to the users and this euphoria is the cause for addiction.(Kwon et al. 2011) Most inhalant drugs are non-medically used ingredients in household or industrial chemical products and are not intended to be concentrated and inhaled. A small number of recreational inhalant drugs are pharmaceutical products that are used illicitly. Inhalants can be classified by their intended function
Francis Acquah
Mental Health Foundation of Ghana, Australia
Title: Transforming Mental Health Services in Ghana: Blending traditional healing
Biography:
Francis Acquah Born in West Africa, Francis qualified as a Mental Health Nurse in the United Kingdom and is a Credentialed Mental Health Nurse accredited by the Australian College of Mental Health Nurses. He has over 25 years of experience across youth, adult, public and private health care in Australia and the United Kingdom and has undertaken a range of roles, including clinical, managerial and educational. He has also served as a Specialist Pharmaceutical advisor for a leading pharmaceutical company.
Abstract:
The West African country of Ghana is situated just north of the equator bordering the Atlantic Ocean. Ghana’s tropical beaches and picturesque countryside are starkly contrasted by the destitute and inhumane living environments of people living with mental health conditions who often find themselves subjected to archaic treatment regimes as articulated in the report “Like a Death Sentence”, Human Rights Watch (2012). The MHFGH was formed as a direct result of this report and comprises mental health professionals and academics mainly based in the diaspora. It is a registered charity and contributes to government, community and private efforts to promote mental health and wellbeing, and reduce stigmatisation of mental illness in Ghana.
Jacqueline Heron
Registered Psychotherapist, Canada
Title: Why Trauma Informed Counselling is an Essential component of Women’s Addiction Treatment
Biography:
Ms. Jacqueline Heron has completed her Master degree in Counselling Psychology from the University of Toronto and a Master degree in Education from Central Michigan University. She works at Toronto Western Hospital as a Addiction Clinician and she also has a Psychotherapy practice in Toronto.
Abstract:
Women who are seeking addiction treatment often present with complex spectrum of issues, a history of trauma is often most specific to these presenting issues. Unfortunately, due to the stigma that is attached to women and addiction, trauma symptoms are often not detected and explored when women present for addiction treatment. Failing to address trauma symptoms can have devastating implications on the effectiveness of addiction treatment, which may result poor therapeutic rapport and disengagement in treatment.
Gregory Rudolf
American Board of Addiction Medicine, USA
Title: Buprenorphine in the treatment of opioid-induced hyperalgesia
Biography:
Abstract:
Nachum Dafny
University of Texas Health Science Center at Houston, USA
Title: Behavioural and electrophysiological study of nucleus accumbens
Biography:
Nachum Dafny has received his MS and PhD degrees from Hadassah Medical School in Jerusalem in 1965 and 1969, respectively followed by Post-docs at
Abstract:
Angela DB Reed
Turning Point INC., USA
Title: TPI goes beyond providing culturally competent to culturally specifi c
Biography:
Abstract:
- Mental Health and Addiction Medicine
Session Introduction
Pamela Montazer
Pepperdine University, USA
Title: Examining the Need for Trauma Informed Therapy in Dual Diagnosis Treatment
Biography:
Pamela Montazer has completed her M.A. from Pepperdine University. She is a licensed Marriage and Family Therapist in the sate of California and has completed EMDR training. She currently works in dual diagnosist treatment and in private practice in Orange Country, California.
Abstract:
Leading authorities and researchers in the in the field such as Gabor Mate and Jacobsen, Southwick, & Kosten, (2001) have examined the co-occurrence of trauma and substance abuse. However, despite the growing buzz on trauma informed therapy there has been relatively little discussion on the possible efficacy of trauma informed therapy in dual diagnosis treatment and there continues to be sparse implementation of evidenced based trauma informed therapy in dual diagnosis treatment. The purpose of this article is to review current literature and research examining the utility of trauma informed interventions such as EMDR (Eye Movement Desensitization and Reprocessing) in dual diagnosis treatment. Examining current literature and research on trauma and substance abuse elucidates a clear connection between the two and a need for trauma informed therapy in dual diagnosis treatment. Trauma must be adequately addressed for comprehensive and successful substance abuse/ dual diagnosis treatment. In conclusion, examining the current literature and research on trauma and substance abuse sheds new light on the need for increased implementation of trauma informed therapy in dual diagnosis treatment.
Gregory Rudolf
American Board of Addiction Medicine, USA
Title: Non-Opioid Protocol for Opioid Detoxification and/or Transition to Antagonist Treatment
Biography:
Rudolf has been board-certified by the American Board of Addiction Medicine since 2004, by the American Board of Family Medicine since 2003, and by the American Academy of Medical Acupuncture since 2010. He divides his clinical time between inpatient addiction medicine at Cascade Behavioral Hospital in Seattle, where he is medical director of addiction recovery services, and Swedish Pain Services, where he practices outpatient pain management, addiction medicine, and medical acupuncture. His research has been inspired by his breadth of clinical experience. He has developed a novel protocol for opioid withdrawal management which has a range of clinical applications among the available treatment options for opioid use disorders, and which has been the subject of research presented at this and other conferences.
Abstract:
The clinical effectiveness of a novel non-opioid and benzodiazepine-free protocol was compared to a buprenorphine/naltrexone taper for opioid detoxification and transition to subsequent relapse prevention strategies, including initiation of extended release (ER) naltrexone treatment. Methods: Retrospective chart review of DSM IV diagnosed opioid-dependent patients admitted for inpatient detoxification examined differences between 84 non-opioid protocol (treated with scheduled 4-day tizanidine, hydroxyzine and gabapentin) and 40 bup/nx protocol (treated with scheduled 4-day bup/nx taper) subjects. Both groups received ancillary medications and routine counseling. Primary outcomes measured completion of detoxification and facil- itation to further chemical dependency treatment. Secondary outcomes in- cluded length of stay (LOS), adverse effects, Clinical Opiate Withdrawal Scale (COWS) scores, ancillary medication use, and initiation of injectable ER naltrexone treatment.
Kun-Hua Lee
National Dong Hwa University, Taiwan
Title: The relationships among depression, withdrawal symptoms and compulsion among heroin abuser with methadone replacement treatment in Taiwan
Biography:
Abstract:
Diane Mintz
Mental Health Advocate & Business Owner, USA
Title: The impact of hearing stories of recovery from dual diagnosis
Biography:
Abstract:
Melissa Alton
LMHC, NCC, CCMHC, EMDR in Private Practice, USA